vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and Eightco Holdings Inc. (ORBS). Click either name above to swap in a different company.
Eightco Holdings Inc. is the larger business by last-quarter revenue ($10.2M vs $9.5M, roughly 1.1× Cellectis S.A.). Cellectis S.A. runs the higher net margin — -265.9% vs -2281.6%, a 2015.7% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -49.9%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-11.0M).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
CLLS vs ORBS — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $10.2M |
| Net Profit | $-25.3M | $-232.5M |
| Gross Margin | — | -13.0% |
| Operating Margin | -181.1% | -475.0% |
| Net Margin | -265.9% | -2281.6% |
| Revenue YoY | 375.0% | -49.9% |
| Net Profit YoY | -51.9% | -9183.3% |
| EPS (diluted) | $-0.28 | $-2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $10.2M | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | — | $7.6M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | — | $20.3M | ||
| Q3 24 | — | $6.1M | ||
| Q2 24 | $9.5M | $5.3M | ||
| Q1 24 | — | $8.0M |
| Q4 25 | — | $-232.5M | ||
| Q3 25 | — | $-25.8M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-2.5M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | — | $-3.2M | ||
| Q2 24 | $-25.3M | $4.4M | ||
| Q1 24 | — | $1.9M |
| Q4 25 | — | -13.0% | ||
| Q3 25 | — | -3.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 25.1% | ||
| Q1 24 | — | 17.5% |
| Q4 25 | — | -475.0% | ||
| Q3 25 | — | -116.9% | ||
| Q2 25 | — | -15.9% | ||
| Q1 25 | — | -14.3% | ||
| Q4 24 | — | -11.9% | ||
| Q3 24 | — | -29.1% | ||
| Q2 24 | -181.1% | -16.4% | ||
| Q1 24 | — | -39.6% |
| Q4 25 | — | -2281.6% | ||
| Q3 25 | — | -487.6% | ||
| Q2 25 | — | -15.4% | ||
| Q1 25 | — | -25.7% | ||
| Q4 24 | — | -12.3% | ||
| Q3 24 | — | -52.5% | ||
| Q2 24 | -265.9% | 84.2% | ||
| Q1 24 | — | 24.4% |
| Q4 25 | — | $-2.34 | ||
| Q3 25 | — | $-0.58 | ||
| Q2 25 | — | $-0.38 | ||
| Q1 25 | — | $-0.84 | ||
| Q4 24 | — | $-1.44 | ||
| Q3 24 | — | $-1.77 | ||
| Q2 24 | $-0.28 | $2.15 | ||
| Q1 24 | — | $1.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $58.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $232.6M |
| Total Assets | $407.1M | $250.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $58.5M | ||
| Q3 25 | — | $23.7M | ||
| Q2 25 | — | $696.3K | ||
| Q1 25 | — | $434.4K | ||
| Q4 24 | — | $239.2K | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | $149.0M | $363.1K | ||
| Q1 24 | — | $808.8K |
| Q4 25 | — | $232.6M | ||
| Q3 25 | — | $339.2M | ||
| Q2 25 | — | $8.9M | ||
| Q1 25 | — | $9.7M | ||
| Q4 24 | — | $11.9M | ||
| Q3 24 | — | $13.0M | ||
| Q2 24 | $148.6M | $13.8M | ||
| Q1 24 | — | $3.9M |
| Q4 25 | — | $250.2M | ||
| Q3 25 | — | $355.5M | ||
| Q2 25 | — | $48.7M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | — | $50.8M | ||
| Q3 24 | — | $49.2M | ||
| Q2 24 | $407.1M | $48.4M | ||
| Q1 24 | — | $50.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-11.0M |
| Free Cash FlowOCF − Capex | $27.6M | $-11.0M |
| FCF MarginFCF / Revenue | 290.5% | -107.7% |
| Capex IntensityCapex / Revenue | 13.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-659.2K | ||
| Q1 25 | — | $999.8K | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | — | $77.7K | ||
| Q2 24 | $28.9M | $-440.3K | ||
| Q1 24 | — | $-723.3K |
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-661.3K | ||
| Q1 25 | — | $999.7K | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | — | $73.0K | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -107.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -8.7% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | — | -32.7% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | 290.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | 13.2% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.10× | ||
| Q1 24 | — | -0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
